ADAM8 as a drug target in pancreatic cancer

Uwe Schlomann, Garrit Koller, Catharina Conrad, Taheera Ferdous, Panagiota Golfi, Adolfo Molejon Garcia, Sabrina Höfling, Maddy Parsons, Patricia Costa, Robin Soper, Maud Bossard, Thorsten Hagemann, Rozita Roshani, Norbert Sewald, Randal R. Ketchem, Marcia L. Moss, Fred H. Rasmussen, Miles A. Miller, Douglas A. Lauffenburger, David A. Tuveson, Christopher Nimsky and Jörg W. Bartsch ()
Additional contact information
Uwe Schlomann: King’s College London, Institute for Pharmaceutical Science and KCLDI
Garrit Koller: King’s College London, Institute for Pharmaceutical Science and KCLDI
Catharina Conrad: Marburg University, , Baldingerstrasse, 35033 Marburg, Germany
Taheera Ferdous: King’s College London, Institute for Pharmaceutical Science and KCLDI
Panagiota Golfi: King’s College London, Institute for Pharmaceutical Science and KCLDI
Adolfo Molejon Garcia: King’s College London, Institute for Pharmaceutical Science and KCLDI
Sabrina Höfling: King’s College London, Institute for Pharmaceutical Science and KCLDI
Maddy Parsons: King’s College London, Randall Institute
Patricia Costa: Institute of Cancer and Inflammation, St Mary’s School of Medicine, John Vane Building, Charterhouse Square
Robin Soper: Institute of Cancer and Inflammation, St Mary’s School of Medicine, John Vane Building, Charterhouse Square
Maud Bossard: Institute of Cancer and Inflammation, St Mary’s School of Medicine, John Vane Building, Charterhouse Square
Thorsten Hagemann: Institute of Cancer and Inflammation, St Mary’s School of Medicine, John Vane Building, Charterhouse Square
Rozita Roshani: Institute of Cancer and Inflammation, St Mary’s School of Medicine, John Vane Building, Charterhouse Square
Norbert Sewald: Bielefeld University
Randal R. Ketchem: Therapeutic Discovery, AMGEN Inc.
Marcia L. Moss: Biozyme Inc.
Fred H. Rasmussen: Biozyme Inc.
Miles A. Miller: Massachusetts Institute of Technology
Douglas A. Lauffenburger: Massachusetts Institute of Technology
David A. Tuveson: Cold Spring Harbor Laboratory
Christopher Nimsky: Marburg University, , Baldingerstrasse, 35033 Marburg, Germany
Jörg W. Bartsch: King’s College London, Institute for Pharmaceutical Science and KCLDI

Nature Communications, 2015, vol. 6, issue 1, 1-16

Abstract: Abstract Pancreatic ductal adenocarcinoma (PDAC) has a grim prognosis with

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms7175 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms7175

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms7175

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().